Three different molecular tests have been validated as providing useful data that can help a man and his doctors to come to decisions about the management and treatment of localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Decipher, genetic, genomic, molecular, Oncotype, PROLARIS, test | 2 Comments »
In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled … READ MORE …
Filed under: Uncategorized | Tagged: DNA, genetic, genomic, germline, test | 2 Comments »
Many people are increasingly interested in whether genetic testing can help them to understand their risk for cancer. The basic answer is that “Yes, it can.” However, what is also clear is that it is only going to be helpful for a small percentage of the population. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: genetic, genomic, germline, risk, test | 1 Comment »
One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests actually telling us compared to the clinical data?” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, genetic, genomic, prognosis, risk, test | 2 Comments »
Over the past few years, with the increased focus on the idea of “personalized” medicine, we have become increasingly informed about and focused on correlations between genetics and genomics and risk for prostate cancer. However, … READ MORE …
Filed under: Diagnosis, Risk | Tagged: familial, genetic, grandsons, hereditary, risk, sons | 4 Comments »
There’s a very nice article today on the MedPage Today web site about the medical value of “at-home genetic testing” (i.e., the sorts of tests available from companies like 23&Me and some others). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: genetic, test, utility, value | 3 Comments »
Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of European ancestry at this time). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: aggressive, data, genetic, genomic, predict, risk, testing | 2 Comments »
Knowing whether you carry inherited cancer risk genes can help you to make the best decisions for your treatment and for your family. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: counseling, genetic, medicine, precision, testing | 1 Comment »
A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: biopsy, genetic, inconsistency, liquid, medicine, personalized, problem, result, test | 2 Comments »
Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: 3βHSD1, ADT, genetic, germline, HSD3B1, profile, response, Treatment | Leave a comment »
A newly published paper in the journal JCO Precision Oncology confirms what many of us may have suspected — that the practical application of somatic tissue testing to clinical decision-making was low prior to 2015 . … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: genetic, genomic, genotyping, immunohistochemistry, medicine, molecular, precision, test | 25 Comments »
A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: analysis, genetic, genomic, targeted, testing, therapy | 2 Comments »
